Notes and Quotes
Simplifying and adapting antiretroviral treatment in resource-poor settings
Does transient HAART during primary HIV-1 infection lower the virological set-point?
Rapid dissemination of SIV following oral inoculation
CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy
Pharmacogenetics of efavirenz and central nervous system side effects
Treatment interruption for virological failure or as sparing regimen in children with chronic HIV-1 infection
The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001
Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users
First identification of HIV-1 groups M and O dual infections in Europe
Male circumcision and the risk of sexually transmitted infections and HIV in Rakai, Uganda
F-18-Fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients
Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence
C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen
Soluble toll-like receptor 2 in HIV infection
Intestinal spirochetosis and diarrhea, commensal or causal
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related
HIV-1 group M superinfection in an HIV-1 group O-infected patient
Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS
Response to ‘Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence’ by Smith et al.
More on abacavir-induced neuropsychiatric reactions
Index to authors